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There are many different biochemical processes responsible for the hepatocelluar carcinoma (HCC) 
development that can be targeted for the prevention or halt progression of the HCC. Non-selective beta-
blockers (NSBB) affects a multitude of intracellular biochemical and signaling pathways involved in 
carcinogenesis. Aim: To determine if NSBB may be protective for HCC in patients with cirrhosis and 
portal hypertension. Methods: We retrospectively enrolled 200 patients from medical records diagnosed 
with cirrhosis and portal hypertension between January 2001 and December 2013. Eighteen patients were 
excluded (taking selective beta-blocker and/or unavailable medical records). The etiology of cirrhosis, use 
of NSBB, demographics and the presence of HCC was collected. Result: There were 140 males and 42 
females. The mean age for portal hypertension with cirrhosis without HCC was 53.5 ± 11.4 & with HCC 
was 62.2 ± 9.5 years. Univariate analysis of the association of NSBB with HCC yielded OR = 0. 11 (95% CI: 
0.04 to 0.25); p < 0.0001, suggesting a protective effect of NSBB.  Multivariable analysis suggests virtually 
no change when the Odds ratio (OR) was adjusted for diabetes mellitus (DM), alcohol use, Hepatitis B virus 
(HBV) status, Black race and age ≥ 53. There was a slight increase in the OR adjusted for statin use. 
Conclusion: This study highlights association of NSBB use in the patients with liver cirrhosis and portal 
hypertension for prevention of HCC.  
 [N A J Med Sci. 2015;8(3):105-108.   DOI:  10.7156/najms.2015.0803105] 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the fifth most common 
cancer in men and seventh most common cancer in women.
1
 
According to American Cancer Society, about 30,000 new 
cases are diagnosed each year. Major risk factors for 
development of HCC include hepatitis C virus infection 
(HCV), hepatitis B virus infection (HBV), alcoholic liver 
disease and nonalcoholic fatty liver disease (NAFLD), but 
virtually cirrhosis of almost any cause is the risk factor. Age-
adjusted incidence of the HCC has been going up in recent 
decades. The incidence has almost doubled in the past two 
decades and it is expected to continue to rise as a 
consequence of high hepatitis C infection rates between 1960 
and 1990.
2
  
 
There are many biochemical processes responsible for the 
HCC development that can be targeted for the prevention or 
halt progression of the HCC. Various biochemical processes 
include (1) increased level of reactive oxygen species (ROS) 
mediated lipid peroxides, which participate in chain reactions 
that amplify damage to bio molecules, including DNA and at 
the end result of DNA attack gives rise to the mutations that 
may involve tumor suppressor genes or oncogenes, and cause 
cancer.
3
 (2) Mitochondria are crucial for cellular energy 
production, cell survival and major regulator in the intrinsic 
apoptotic pathway so mitochondrial dysfunction by certain 
gene mutations in mitochondria may lead to cause apoptotic 
resistance, evolves into hepatocarcinogenesis and promote 
HCC progression.
4
 (3) HCV proteins trigger ROS generation 
through induction of NADPH oxidase 4 expressions and 
autocrine TGFβ-dependent mechanism. The ROS then 
activates mitogen-activated proteins, extracellular signal–
regulated kinases, or angiogenesis along with induction of 
DNA damage.
5
 (4) Vascular endothelial growth factor 
(VEGF) is associated with the development of liver tumor 
neovascularization and basic fibroblast growth factor (FGF) 
is involved in infiltration of cancer cells into the tumor 
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capsule in HCC.
6
 (5) Linear relation exists between level of 
catecholamines and severity of liver disease. More advanced 
disease is associated with higher levels of catecholamines.
7
 
(6) Bacterial translocation, across the edematous bowel wall, 
represents a large inflammatory load to the cirrhotic liver. It 
exposes hepatocytes to chronic inflammation, thus 
contributing to carcinogenesis.
8
  
 
Non-selective beta-blockers (NSBB) affects a multitude of 
above mentioned intracellular biochemical and signaling 
pathways involved in carcinogenesis. These include (1) 
preventing lipid peroxidation of the membranes, (2) 
attenuating mitochondrial dysfunction, (3) inhibiting Bax-
mediated cytochrome C release, NADPH oxidase and protein 
kinase C activity, (4) decreasing vascular endothelial growth 
factor (VEGF) / basic fibroblast growth factor gene 
expression. (5) antagonizing catecholamine driven cell 
migration, tumor angiogenesis, invasiveness and proliferation 
(6) decreasing bacterial translocation and reducing the partial 
load of pro inflammatory bacterial products. (7) preventing  
or reducing cancer progression, by inhibiting cAMP-
responsive element-binding protein (CREB), NF-κB, and 
activator protein (AP-1), inducting apoptosis, or reducing 
matrix metalloproteinase (MMP)-9 activation and tumor 
angiogenesis.
9-16
 
 
Because NSBB are regularly used as prophylaxis for portal 
hypertension in cirrhotic liver disease, the purpose of this 
study was to look for a possible association of NSBB with 
HCC. 
 
 
 
 
Figure 1. Flow chart of the protocol. 
 
 
METHODS 
Protocol, patients and setting 
This is a retrospective analysis of 200 consecutive patients, 
age ≥ 18 years, from Jan 2001 to 31 Dec 2013, with a 
diagnosis of portal hypertension and cirrhosis, with or 
without HCC.   The institution at which the study was 
conducted is a 700-bed tertiary-care teaching hospital in 
northeastern USA.  Excluded from the original cohort were 
16 patients taking a selective β blocker and 2 patients for 
whom insufficient data were available.  The flow chart of the 
study is shown in Figure 1. 
 
The study was given exempt status by the Institutional 
Review Board of St. Joseph’s Healthcare System, which 
operates the center where the study was conducted. 
Statistical analyses 
For this study, α was set at 0.05; thus values of p < 0.05 were 
required for statistical significance.  Potential confounders 
were considered as covariates if baseline differences between 
the groups had a p-value ≤ 5α, i.e., p ≤ 0.25. The continuous 
variable (age) was found to be not significantly different 
from a normal distribution by the D’agostino-Pearson 
omnibus normality test.  Therefore age is expressed as mean 
±1. Standard deviation (SD) and between-group age 
differences evaluated by the t-test.  The cutoff for 
dichotomizing age for the two groups was determined by 
receiver operating characteristic (ROC) curve analysis. 
 
For categorical variables, univariate association was 
evaluated by cross-tabulating exposures with the outcome 
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and tested for statistical significance with Fisher’s exact test 
for 2 x 2 contingency tables and with chi-square for tables 
with larger numbers of cells (race/ethnicity).  Because of the 
retrospective nature of the  study,  the odds ratio (OR)  and 
95% confidence interval (95% CI) was used as a measure of 
effect size.  Multivariable association, using covariates as 
described, above, was assessed by binary logistic regression. 
 
Analyses were conducted using the Prism® software 
(GraphPad Corp., San Diego, CA, USA) and SPSS® v. 21 
(IBM Corp., Armonk, NY, USA). 
 
Table 1. Baseline Demographics. 
Characteristics HCC Present (42) HCC Absent (140) p- value 
Age (Mean± SD) 62.2 ± 9.5 53.5 ± 11.4 < 0.0001 
Gender (F/M) 7/35 35/105 0.303 
Race/Ethnicity   0.242 
Black vs all others 12 21 0.066 
Hispanic vs all others 19 77 0.291 
White vs all others 8 33 0.675 
Others vs all others 3 9  
DM (+/-) 9/33 47/93 0.182 
HCV (+/-) 21/21 57/83 0.283 
HBV (+/-) 8/34 13/127 0.099 
Ethanol use (+/-) 16/26 77/63 0.078 
Statin use (+/-) 5/37 4/136 0.032 
 
RESULTS 
Baseline Characteristics of the Subjects 
Table 1 gives the demographic and clinical characteristics of 
the two groups. There were 140 males and 42 females. The 
mean age for portal hypertension with cirrhosis without HCC 
was 53.5 ± 11.4 & HCC was 62.2 ± 9.5 years. The 
distribution of race was 96 (52.7%) Hispanic & 41 (22.5%) 
Caucasian. Causes of cirrhosis were alcohol 93 (51%), 
followed by HCV 78 (42.8%). Ninety-nine (Propranolol = 97, 
Nadolol = 2) patients were on NSBB. Forty-two patients (M 
= 35, F = 7) had a diagnosis of HCC.  Among those 
examined, age, race/ethnicity, diabetes, presence of HBV, 
ethanol and statin use demonstrated p-values ≤ 0.25 and were 
included in the multivariable model. Race/ethnicity data were 
further dichotomized post hoc.  This analysis yielded black 
race (p = 0.066) as a covariate.  
 
Association of NSBB with HCC 
Analysis of the association of NSBB with HCC on a 
univariate base yielded OR = 0. 11 (95% CI: 0.04 to 0.25); p 
< 0.0001, suggesting a protective effect of NSBB.  In males, 
the odds were lower in NSBB [OR 0.112, CI 95% (0.042, 
0.295) p < 0.0001]. Significantly lower odds were also found 
in HCV [OR 0.17, CI 95% (0.056, 0.513) p < 0.0001], 
alcohol [OR 0.039, CI 95% (0.005, 0.309) p < 0.0001], 
Hispanic [OR 0.146, CI 95% (0.044, 0.479) p = 0. 0008] and 
black race [OR 0.062, CI 95% (0.01, 0.386) p = 0. 001]. 
Statistical significance was not reached in females [OR 0.174, 
p= 0.051], HBV subgroup [p = 1] and Caucasian subgroup [p 
= 0. 2]. Multivariable analysis suggests virtually no change in 
the OR and 95% CI when age [at a cutoff of 53 years] (OR: 
0.11, CI: 0.04 to 0.28), black race (OR: 0.1, CI: 0.04 to 0.24), 
HBV status (OR: 0.11, CI: 0.04 to 0.26), ethanol use (OR: 
0.1, CI: 0.04 to 0.24) and diabetes mellitus (OR: 0.1, CI: 0.04 
to 0.25) were included as covariates.  Interestingly, statins 
slightly mitigated the protective effect of NSBB, the OR, 
adjusted for statins, was 0.12 (95% CI: 0.05 to 0.29). (Figure 
2) 
 
 
 
 
Figure 2. Forest plot comparing univariate OR and 95% confidence interval 
(CI) with those adjusted for covariates. 
 
 
DISCUSSION 
In our study, we assessed the association of NSBB in the 
HCC prevention in patients with cirrhosis and portal 
hypertension.  We found that NSBB treatment is associated 
with lower incidence of the HCC in patients with cirrhosis 
and portal HTN. 
 
As the incidence of HCC is increasing, it is important for us 
to look for preventive measures to stop the growing burden 
and health care cost of HCC.
2
 Use of HBV vaccination 
dramatically reduced the prevalence of HBV infection and 
there has been a concomitant decrease in the incidence of 
hepatocellular carcinoma.
17
 The literature suggests the use of 
antiviral therapy to control HBV and HCV infection and 
achieving sustained viral response substantially reduces but 
does not eliminate the risk of HCC.
18-20
  Statin use also has 
been associated with a lower risk of HCC in patients with 
HBV and HCV infection.
21-22
 One common limitation exists 
with all above-mentioned preventive interventions; that is, 
once cirrhosis is established the effectiveness of these 
interventions to prevent HCC development and progression 
is questionable.
18,20-23
 While, NSBB is the only intervention 
which might work in the patients with advanced cirrhosis to 
prevent HCC.
5
  
 
To our knowledge, two retrospective studies have been done 
so far to evaluate the protective effect of NSBB in the 
patients with cirrhosis. Nkontchou et al retrospectively 
reviewed 291 patients with compensated hepatitis C virus 
related cirrhosis showed NSBB use decreased HCC 
incidence.
5
 Kim et al reviewed 273 patients with all cause 
cirrhosis and it did not show any relation between NSBB and 
HCC incidence.
24
 There are many other benefits of NSBB 
reported in the literature for cirrhotic patients and some 
tumors. NSBB has been shown to decrease mortality in 
patients with cirrhosis via reducing the rate of gastrointestinal 
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bleeding and decreasing incidence of spontaneous bacterial 
peritonitis.
25,26
 In ovarian and breast cancer NSBB has shown 
promising results in tumor prevention and growth.
27,28
 The 
anti-angiogenic effects of NSBB in hemangiomas are well 
documented.
29
 
 
It is clear from our study that individuals who were not on 
the NSBB were more likely to develop HCC. NSBB is easily 
available, affordable and are also well tolerated by most of 
the patients. So this strategy may decrease incidence of HCC 
in patients with cirrhosis. 
 
Major limitation of our study are unknown compliance and 
duration of NSBB therapy, duration from onset of portal 
HTN to development of HCC, and data regarding antiviral 
therapy. Short follow up period which is 3 years.  
 
CONCLUSION 
This study highlights association of NSBB use in patients 
with liver cirrhosis and portal hypertension for prevention of 
HCC. It is also clear that further studies, especially 
randomized control trial need to be carried out to evaluate the 
importance of NSBB in HCC prevention. If favorable effects 
of NSBB will be confirmed in such a trial, this would be 
significant since the majority of cirrhotic patients would need 
beta blockers and they are at the high risk for HCC. 
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